

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CK Life Sciences Int'l. (Holdings) Inc.

長江生命科技集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 0775)

**RESIGNATION OF EXECUTIVE DIRECTOR,
VICE PRESIDENT AND CHIEF EXECUTIVE OFFICER
AND
RE-DESIGNATION OF EXECUTIVE DIRECTOR**

The Board of Directors (the “Board”) of CK Life Sciences Int’l., (Holdings) Inc. (the “Company”) announces that with effect from 8th May, 2026, Mr. Lance Richard Lee Yuen (“Mr. Yuen”) has resigned as Executive Director, Vice President and Chief Executive Officer of the Company, but will remain director of the Company’s Canadian subsidiaries to oversee the business there. Owing to personal and family matters, Mr. Yuen needs to relocate out of Hong Kong to his home country of Canada. The Board would like to express their sincere gratitude to Mr. Yuen for his invaluable contributions to the Company during his tenure as Executive Director, Vice President and Chief Executive Officer of the Company and his ongoing commitment in an important part of the Company’s business in Canada.

In accordance with the requirements of Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”), Mr. Yuen has confirmed that he has no disagreement with the Board and that he is not aware of any matters relating to his resignation that need to be brought to the attention of the shareholders of the Company.

The Board further announces that Mr. Yu Ying Choi, Alan Abel (“Mr. Yu”), an Executive Director, is re-designated from his current position of Deputy Chairman to Deputy Chairman and Chief Executive Officer of the Company with effect from 8th May, 2026.

Set out below is the biographical profile of Mr. Yu:

Mr. Yu Ying Choi, Alan Abel

Yu Ying Choi, Alan Abel, aged 70, is the Deputy Chairman of the Company. Mr. Yu has been a member of the Executive Committee of the Company since February 2021. Mr. Yu acted as the Vice President and Chief Executive Officer of the Company from September 2020 to September 2024 and acted as the Vice President and Chief Operating Officer of the Company from June 2002 to September 2020. He is also a Director of Dogwood Therapeutics, Inc. (listed in the United States). He holds a Bachelor of Arts degree and a Master’s degree in Business Administration and is a fellow member of The Hong Kong Institute of Directors.

Mr. Yu does not have any relationship with any other Directors, senior management or substantial or controlling shareholders of the Company. Mr. Yu has a personal interest of 2,250,000 shares of the Company within the meaning of Part XV of the Securities Futures Ordinance. The Director's fee of Mr. Yu as an Executive Director and Deputy Chairman and Chief Executive Officer of the Company is HK\$100,000 per annum, subject to shareholders' approval at the forthcoming annual general meeting of the Company. The emoluments of Executive Directors of the Company are determined by reference to the Company's performance and profitability, as well as the prevailing market conditions.

Save as disclosed above, there are no other matters concerning Mr. Yu's re-designation to Deputy Chairman and Chief Executive Officer of the Company that need to be brought to the attention of the shareholders of the Company nor is there any information required to be disclosed pursuant to the requirements of Rule 13.51(2) of the Listing Rules.

By Order of the Board
CK Life Sciences Int'l., (Holdings) Inc.
Eirene Yeung
Company Secretary

Hong Kong, 8th May, 2026

As at the date of this announcement, the Executive Directors of the Company are Mr. Li Tzar Kuoi, Victor (Chairman), Mr. Kam Hing Lam, Mr. Ip Tak Chuen, Edmond, Mr. Yu Ying Choi, Alan Abel and Dr. Toh Kean Meng, Melvin; and the Non-executive Directors are Mr. Peter Peace Tulloch, Mrs. Kwok Eva Lee (Independent Non-executive Director), Mr. Kwan Kai Cheong (Independent Non-executive Director), Mr. Paul Joseph Tighe (Independent Non-executive Director) and Mr. Donald Jeffrey Roberts (Independent Non-executive Director).